 |
Mike Rothe, Ph.D.
|
Chief Executive Officer
|
| Guoqing Chen, Ph.D. |
Vice President of Research |
 |
David V. Goeddel, Ph.D.
|
Chairman |
| John D. Diekman, Ph.D. |
| Carl L. Gordon, Ph.D., CFA |
| Robert Schreiber, Ph.D. |
| Mike Rothe, Ph.D. |
 |
Robert Schreiber, Ph.D.
|
Chairman |
| Frederick Appelbaum, M.D. |
|
| Thomas Kipps, M.D., Ph.D. |
|
| Richard Klausner, M.D. |
|
| Jeffrey V. Ravetch, M.D., Ph.D. |
|
| Richard Ulevitch, Ph.D. |
|
| Emil Unanue, M.D. |
|
| |
| |
| |
|
|
 |
Igenica has assembled a management team with deep operational experience and strong antibody drug discovery expertise. Supported by a Scientific Advisory Board that comprises key thought leaders in the fields of oncology and immunology and advised by an experienced Board of Directors with a track record of success in the industry, Igenica is well positioned to realize its mission of discovering and developing breakthrough therapeutics for the treatment of cancer. |
|